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P rofessor Ikegami provides a careful and wide-ranging critique of the alternatives to fee-for-service (FFS) payment systems. 1 Excellent arguments against the several alternatives to FFS, however, is not a necessarily a good defense of FFS, especially if the pro-FFS arguments are marred with several inaccuracies as applied to the United States, which is a key player in Professor Ikegami's Editorial. Equally disconcerting, I see notable weaknesses in his proposals to improve FFS payment plans. He starts with an excellent summary of the problems with FFS. Then, however, his presentation of the facts suggests lack of familiarity with the United States system, which he uses as a touchstone case. He says that "cost escalations, inequality and high administrative costs" are associated with each player "seeking to game (I think he means "gain") at the expense of the other." And he says that prices are set by the private health insurance plans. Let's look at these statements: It is true that each discipline seeks to increase its reimbursements, but it is not a zero sum game, and costs continue to increase across the board. "My specialty is more deserving than your specialty" is not the cause of escalation.
2,3 Also, and more important, while private insurance companies are active in setting some rates, they act to bring prices down, not up. They want to pay as little as possible for as few services as possible. Even more directly, the majority of medical cost prices-and usually the determination of what will be "covered"-are not set by private insurance companies, but rather covered services are primarily set by agencies of the federal government: Medicare and Medicaid. 4, 5 Professor Ikegami appears to neither comprehend nor incorporate the rule-setting functions of Medicare and Medicaid. Worse, he misses the overwhelming role of the big pharmacy industry-which has successfully lobbied congress to prevent many federal agencies from buying drugs at lower prices, and which also prevents importation of drugs from nations without captured regulatory processes, eg, most of the world except the United States. The cost of medications is a significant part of healthcare inflation, and is not a part of FFS. We shall not review his superb critiques of the alternative payment systems: health maintenance organizations (HMOs), pay-for-performance, diagnosis-related groups (DRGs), etc. But we single out his argument against pay-for-performance as especially cogent. We turn now to his recommendations for improving FFS. Alas, many of his recommendations have been tried and most have failed. 3. Professor Ikegami suggests that the cost of medical devices will be driven down by competition. That is simply not true in the United States, at least. Regulatory capture, restrictions on entry into the market, and other factors have had the opposite effect. 4. Professor Ikegami writes that the introduction of new technologies will drive down prices. In the United States, the opposite has occurred. For large hospital systems, electronic health records (EHRs) cost hundreds of millions of dollars to purchase and billions of dollars to install. 7 For ambulatory care and smaller hospitals the prices are of course lower, but still massively expensive. Magnetic resonance imagines (MRIs) are now common and cost many millions. He says that electronic billing will make the process more efficient and transparent. In the United States, it is absolutely not true. First, because of the interplay of government regulators, insurance companies, and several (often conflicting laws) the prices are completely non-transparent. 8 For example, a hospital might have a listed charge for a service (say, inserting an artificial knee) of $35 000, but the various insurance companies will actually pay $4000, and the copays from individual patients will vary from $100 to $31 000. 8, 9 Moreover, there will be additional fees from the anesthesiologist (with the same range of costs and payments), for operating room time, etc. In fact, most hospital bills are incomprehensible even to experts, and many are often flat out wrong. 8, 9 Professor Ikagami raises many excellent points and is undoubtedly well-intended and knowledgeable about many national health systems. His critique of non-FFS systems is spot on. But his use of the United States as an example and as a source of lessons is problematic. In fact, the United States is moving increasingly toward "accountable care organization" payment plans, where the hospital or medical system assumes the cost and risk for all care. It is the exact opposite of FFS payment systems. [10] [11] [12] [13] In sum, his argument and hope for FFS as a solution to rising prices is not a convincing position.
Ethical issues
Not applicable.
